Abstract
Abstract
Valvular heart abnormalities have been reported in patients with Parkinson’s disease (PD) treated with pergolide. However, the incidence and severity of these abnormalities vary from study to study and their course after drug withdrawal has not been systematically assessed.
Objectives
To estimate the frequency and severity of valvular heart abnormality and its possible reversibility after drug withdrawal in a case-control study.
Methods
All PD patients in the Amiens area treated with pergolide were invited to attend a cardiologic assessment including transthoracic echocardiography. Thirty PD patients participated in the study. A second echocardiography was performed (median interval: 13 months) after pergolide withdrawal (n = 10 patients). Controls were age- and sexmatched non-PD patients referred to the cardiology department.
Results
Compared to controls, aortic regurgitation (OR: 3.1; 95 % IC: 1.1–8.8) and mitral regurgitation (OR: 10.7; 95 % IC: 2.1–53) were more frequent in PD patients (tricuspid: NS). The number of affected valves (n = 2.4 ± 0.7) and the sum of regurgitation grades (n = 2.8 ± 1.09) were higher (p = 0.008 and p = 0.006, respectively) in the pergolide group. Severity of regurgitation was not correlated with pergolide cumulative dose. A restrictive pattern of valvular regurgitation, suggestive of the role of pergolide, was observed in 12/30 (40 %) patients including two with heart failure. Pergolide was discontinued in 10 patients with valvular heart disease, resulting in a lower regurgitation grade (p = 0.01) at the second transthoracic echocardiography and the two patients with heart failure returned to nearly normal clinical examination. This study supports the high frequency of restrictive valve regurgitation in PD patients treated with pergolide and reveals that a significant improvement is usual when the treatment is converted to non-ergot dopamine agonists.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Van Camp G, Flamez A, Cosyn B, et al. (2004) Treatment of Parkinson’s disease with pergolide and relation to restrictive valvular heart disease. Lancet 363:1179–1183
Pritchett Amandal AM, Morrison JF, Edwards WD, et al. (2002) Valvular heart disease in patients taking pergolide. Mayo Clin Proc 77:1280–1286
Van Camp G, Flamez A, Cosyn B, et al. (2003) Valvular heart disease in patients with Parkinson’s disease treated with high-dose pergolide. Neurology 61:859–861
Baseman DG, O’Suilleabhain PE, Reimold SC, et al. (2004) Pergolide use in Parkinson’s disease is associated with cardiac valve regurgitation. Neurology 27:301–304
Waller EA, Kaplan J, Heckman MG (2005) Valvular heart disease in patients taking pergolide. Mayo Clin Proc 80:1016–1020
Zadikoff C, Rochon P, Lang A (2006) Cardiac valvulopathy associated with pergolide use. Can J Neurol Sci 33:27–33
Peralta C, Wolf E, Alber H, Seppik K, Muller S, Bosch S, Wenning GK, Poewe W (2006) Valvular heart disease in Parkinson’s disease vs controls: An echocardiographic study. Mov Disord 21:1109–1113
Serratrice J, Disdier P, Habib G, et al. (2002) Fibrotic valvular heart disease subsequent to bromocriptine treatment. Cardiol Rev 10:334–336
Ruzicka E, Linkova H, Penicka M, Ulmanova O, Novakova L, Roth J (2007) Low incidence of restrictive valvulopathy in patients with parkinson’s disease on moderate dose of pergolide. J Neurol 254(11):1575–1578
Zoghbi WA, Enriquez-Sarano M, Foster E, et al. (2003) Recommendations for evaluation of the severity of native valvular regurgitation with twodimensional and Doppler echocardiography. J Am Soc Echocardiogr 16:777–802
Shaunak S, Wilkins A, Philling JB, Dick DJ (1999) Pericardial, retroperitoneal and pleural fibrosis induced by pergolide. J Neurosurg Psychiatry 66:79–81
Flowers CM, Racoosin JA, Lu SL, et al. (2003) The US food and drug administration’s registry of patients with pergolide-associated valvular heart disease. Mayo Clin Proc 78:730–731
FDA (2003) 2003 Safety Alert-Permax (pergolide mesylate) (http:mermax. htm/www.fda.gov/medwatch/SAFETY/2003)
Kim JY, Chung EJ, Park SW, Lee WY (2006) Valvular heart disease in Parkinson’s disease treated with ergot derivative dopamine agonists. Mov Disord 21:126–134
Yamamoto M, Uesugi T, Nakayama T (2006) Dopamine agonists and cardiac valvulopathy in Parkinson disease: a case-control study. Neurology 67:1225–1119
Zanettini R, Antonini A, Gatto G, Gentile R, Tesei S, Pezzoli R (2007) Valvular heart disease and the use of dopamine agonists for Parkinson’s disease. N Engl J Med 356:39–46
Schade R, Anderson F, Suissa S, Haverkamp W, Garbe E (2007) Dopamine agonists and the risk of cardiacvalve regurgitation. N Engl J Med 356:29–38
Horvath J, Fross RD, Kleiner-Fisher-Fisman G, et al. (2004) Severe multivalvular heart disease: a new complication of the ergot derivative dopamine agonists. Mov Disord 19:656–662
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Dupuy, D., Lesbre, J.P., Gérard, P. et al. Valvular heart disease in patients with Parkinson’s disease treated with pergolide. Course following treatment modifications. J Neurol 255, 1045–1048 (2008). https://doi.org/10.1007/s00415-008-0839-1
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00415-008-0839-1